CHK1 has recently been suggested to represent a therapeutic target in triple-negative breast cancer (TNBC) [28], and its reduced phosphorylation following TLT treatment could explain the selectivity of TLT against BC-CL breast cancers. The gene discussed is CHEK1; the disease is breast carcinoma.